论文部分内容阅读
目的观察尿激酶联合低分子肝素对于治疗急性进展性脑梗死的临床治疗效果。方法将我院同期收治的220例急性进展性脑梗死的患者以随机分配的方式平均分成观察组与对照组,其中各110例患者。两组患者在同时进行常规治疗的情况下,对照组患者使用低分子肝素进行治疗,观察患者在低分子肝素治疗的基础上联合尿激酶进行治疗。连续治疗两周后对患者的神经缺损功能的评分变化进行对比,并且对两组患者的临床疗效进行判定。结果观察组患者和对照组患者的治愈的总有效率分别为85.2%和66.5%,两组患者治疗效果经比较差异性较大(P<0.05),有统计学意义。结论尿激酶联合低分子肝素在治疗急性进展性脑梗死病症方面临床疗效明显,与单纯的低分子肝素治疗相比治疗效果更显著,可在临床中推广使用。
Objective To observe the clinical effect of urokinase combined with low molecular weight heparin on the treatment of acute progressive cerebral infarction. Methods A total of 220 patients with acute progressive cerebral infarction treated at the same period in our hospital were randomly divided into observation group and control group with 110 patients in each group. Two groups of patients in the case of conventional treatment at the same time, the control group of patients with low molecular weight heparin for treatment, observation of patients with low molecular weight heparin therapy based on the combination of urokinase for treatment. Two weeks after continuous treatment of patients with neurological deficit score changes were compared, and to determine the clinical efficacy of the two groups of patients. Results The total effective rates of cure in observation group and control group were 85.2% and 66.5% respectively. There was significant difference (P <0.05) between the two groups in the treatment effect, which was statistically significant. Conclusions Urokinase combined with low molecular weight heparin has obvious curative effect in the treatment of acute progressive cerebral infarction. Compared with simple low molecular weight heparin treatment, the therapeutic effect is more significant and can be widely used in clinic.